human wind generated is better than digital.
Voice, WOODwind, etc brass as well, though water drum and singing bowls and crystal bowls can be finely tuned
Sword in Stone
Words in Tones
There ARE 'magic words'. but the 'key' is the tone(s) and the frequency range(s) of the delivery.
Think 'Om' as example.
ok, don't THINK. the choice is always yours.
Sound healing, sound activation, 'magic words', prayer, laying of hands, all the same reality- directed, tuned frequency effects larger physical substance and solid. Consider the voice, thought, and the subsequent generated wave as a Directed Energy Weapon, or Directed Energy Healing Modality. Or don't. It will exists with or without your acceptance.
>"Must resist truth"
Kek!
Each celestial body, in fact each and every atom, produces a particular sound on account of its movement, its rhythm or vibration. All these sounds and vibrations form a universal harmony in which each element, while having it’s own function and character, contributes to the whole.
Pythagoras (569-475 BC)
deny as you wish. Churches, mosques, cathedrals, ancient architecture, 'stone work', etc all made for or with SOUND.
Mantra, song, 'magic words', etc… Words creat and destroy, but not the words specifically, but the tones enabled by the vocalised, ordered phonetics. Vowels especially.
Every action in life occurs within a field that enables and allows the conditions for it. That field contains constant or modulated waveforms, measured by us in frequency bandwidth.
From how you breath and exist, to how you perceive and think, decompose and heal. All based in part on field and frequency.
journey well, IP hopper.
More than one reason to rethink the use of peptides in vaccine design(2007)
https://www.nature.com/articles/nrd2224
Key Points
T cells constantly survey the body for signs of infection or malignancy through the recognition of fragments of antigens (peptides) complexed to molecules of the major histocompatibility complex.
These peptides (T-cell epitopes) are more diverse than originally thought.
Vaccine design must take into account both chemical modifications to antigens and heterogeneous length of these important targets of immunity, as well as the challenge of the diversity in human immunogenetics.
Peptide-based vaccines offer excellent alternatives to traditional vaccination approaches because of the ease with which chemical modifications can be introduced.
Peptide-based vaccines can be modified to produce peptide mimotopes with enhanced stability, thereby allowing for the precise delivery of the vaccine constituents with fixed peptide length and chemical fidelity.
Vaccines of the future will require a systematic approach to tailor the desired immune response to individuals. Advances in the identification of patient specific epitopes, and delivery, stability and design of peptide therapeutics will open new avenues for vaccine design.
Abstract
The use of peptides as therapeutics is experiencing renewed enthusiasm owing to advances in delivery, stability and design. Moreover, there is a growing emphasis on the use of peptides in vaccine design as insights into tissue-specific processing of the immunogenic epitopes of proteins and the discovery of unusually long cytotoxic T-lymphocyte epitopes broaden the range of targets and give clues to enhancing peptide immunogenicity. Peptides can also be synthesized with known post-translational modifications and/or deliberately introduced protease-resistant peptide bonds to regulate their processing independent of tissue-specific proteolysis and to stabilize these compounds in vivo. We discuss the potential of peptide-based vaccines for the treatment of chronic viral diseases and cancer, and review recent developments in the field of peptide-based vaccines.
https://mobile.twitter.com/Clucky92864053/status/1619694905923878912
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
·
Jan 26
[1]
In 2018, a group of retired military leaders/scientists ranked 33 known bi0weαροns in 12 relevant categories
In 2022, they scored SARS-CoV-2 w/the same rubric
As a potential BW, the COVID-19 virus was 4th-of 34
Food for thought
@KimDotcom
@RWMaloneMD
https://academic.oup.com/milmed/advance-article/doi/10.1093/milmed/usac123/6586077?login=false
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
·
Jan 26
[2]
Civilians typically assume that militaries would want highly lethal germ weapons, but strategically, the opp. is true.
We should all ponder the impl. of SARS-CoV-2 being ahead of all but 3 actual/potential BW's.
The origin DOES matter…
@MaajidNawaz
@Doctor_I_am_The
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
·
Jan 26
[3]
Disturbingly, SARS-CoV-2 was seen by experts as having greater bi0weαροn potential than the Plague, or Marburg [sim. to Ebola]
No one knows that SARS-CoV-2 has an SEB [#7]-like sequence - that overlaps the Furin Cleavage Site.
Btw, SEB antibodies inhibit SARS-CoV-2 in vitro
Clucky
@Clucky92864053
Replying to
@CharlesRixey
@KimDotcom
and 22 others
The exact sequence of SEB is NOT there. The sequence is very short. The shorter the sequence, the more exact it has to be called SEB-like. The FCS is immunogenic it is just NOT SEB. There are some people who claim that structural similarities count but you cannot prove that.
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
·
Jan 27
Replying to
@Clucky92864053
@KimDotcom
and 22 others
Hence the point about antibodies.
It's not just the antibodies - its the manifestation of symptoms / antigenic response similar to MIS-C, TSS, etc
Clucky
@Clucky92864053
·
Jan 27
Replying to
@CharlesRixey
@KimDotcom
and 22 others
SEB is a positive control for t-cell activation experiments. Yes, it is immunogenic. The sequence that would match it to Sars2 is NOT there. There is NO match. There are many t-cell antigens. That does not lead to SEB being contained in the Sars2 sequence as a bioweapon.
Show replies
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
·
Jan 28
Replying to
@Clucky92864053
@KimDotcom
and 22 others
[1]
I didn't claim "proof"
I DID write SEB-like, since that's what 5 groups of researchers called it.
"it is believed that the binding site for these toxins on TCR is on Vβ only & that other var. chains of TCR contribute little"
SEB TCR profile, SEB antibodies, _____?
Charles Rixey, MA MBA (c) 🐭
@CharlesRixey
Replying to
@CharlesRixey
@Clucky92864053
and 23 others
[2]
Thus, I've got a Mil. Virologist [prev. @ Ft. Detrick], who has conducted exp. with SEB toxin
& the same lab that worked with βing Llu before his ☠️, who acknowledged the helpful advice of a certain A. Brufsky [co-author of the MSH-3/19nt paper]
What nukes the hypothesis?
https://mobile.twitter.com/Jikkyleaks/status/1619645116960083968
Jikkyleaks 🐭
@Jikkyleaks
BLOCKED!
The walls are closing in on pharma shills.
In this case
@RealDrJaneRuby
chose to attack
@drcole12
in public to push a fake agenda.
It brought the spotlight on her, revealing a huge corporate opioid scandal involving http://endo.com - a bankrupt pharma company.
Thread:
https://mobile.twitter.com/Jikkyleaks/status/1619509602269425664
p1
3 of 3
https://www.npr.org/2021/04/19/986392991/court-blasts-drug-maker-endo-for-trying-to-improperly-corrupt-opioid-trial
Court Blasts Drugmaker Endo For Trying To 'Improperly Corrupt' Opioid Trial
A state court in Tennessee has punished Endo Pharmaceuticals for improperly withholding a vast trove of documents relating to the sale and marketing of its opioid medication Opana ER.
The judge presiding over the civil trial also concluded the drugmaker and its attorneys made at least a dozen false statements during the pretrial fact-finding process.
"It appears to the court that Endo and its attorneys, after delaying trial, have resorted to trying to improperly corrupt the record," wrote Chancellor E.G. Moody in a judgment issued on April 6.
Endo denies wrongdoing. In a statement emailed to NPR the company said it will appeal the judgement.
But Gerard Stranch, one of the attorneys suing the drugmaker on behalf of local governments in Tennessee, said Endo and its lawyers "conspired to hide the truth" over a period of years as the fact-finding phase of the trial proceeded.
"[Endo's] lawyers crossed the line and worked with the company to subvert the court's orders and then made false statements to the court about it," he said.
Stranch's legal team filed a series of complaints with the court about Endo's conduct in the case, which led to the judge's order.
A controversial opioid, a devastating epidemic
At issue is a lawsuit filed in 2017 by county prosecutors and other local government officials in eastern Tennessee. They claim Endo's opioid medication Opana ER was marketed aggressively in the state without proper safeguards, contributing to high rates of addiction and death.
"The damage is devastating. It has really ripped at the fabric of our community," said Barry Staubus, district attorney in Sullivan County Tennessee.
"It's overdose deaths, it's people losing their jobs, losing their dignity. Almost all our crime is driven by drugs," he told NPR.
Local governments suing the company have demanded roughly $2.4 billion in damages.
Endo ended sales of Opana ER in 2017 after the Food & Drug Administration found it was often abused by people who crushed, dissolved and injected the medication. That misuse also contributed to outbreaks of infectious diseases including HIV and Hepatitis C.
The company faces a wave of opioid-related lawsuits and previously settled other cases with counties in Ohio in 2019 and with the state of Oklahoma last year.
As commonly occurs in litigation, Endo fought in Tennessee to avoid sharing internal documents, communications and memos that describe its business dealings.
But in September 2018, Moody issued an order requiring Endo to divulge detailed information about prescribers it worked with, company efforts to stop abuse of Opana ER, and other opioid-related matters.
A "coordinated strategy" by Endo
In his judgment, Moody found the company violated that order deliberately as "part of a coordinated strategy between Endo and its counsel … to interfere with the administration of justice."
According to Moody's order, Endo's team made at least a dozen false statements during court proceedings and withheld hundreds of thousands of documents, many of them directly relevant to the case.
The court also found some of the documents contradicted sworn testimony provided by Endo witnesses.
One Endo executive testified that the company stopped marketing its opioids to health care providers if their prescribing practices raised safety concerns. According to the company, once a prescriber was placed on the so-called "global exclude" list, they stayed on.
"This was the testimony under penalty of perjury by Endo," Stranch told NPR. "When we got this new tranche of documents we discovered that people went on and off [the list] all the time."
p1
In his order, Moody concluded Endo's behavior was so egregious he was justified in issuing a "default judgment" against the company — effectively skipping the civil trial and finding the company liable for harm caused by the opioid crisis. He noted that plaintiffs have sued for $2.4 billion and "have expert testimony which supports that amount."
"Although this is a harsh sanction, justice demands it under the circumstances. Anything less would make a mockery of the attorneys who play by the rules and the legal system," Moody wrote.
Moody also began a separate legal process in his court designed to identify attorneys who allegedly made false statements and determine what sanctions they might face.
Endo plans to appeal
A spokesperson for Endo Pharmaceuticals declined to be interviewed by NPR.
In a statement, the company said it made a good-faith effort to provide relevant documents and would appeal the judgment. "Endo strongly disagrees with the…court's orders, which it believes are procedurally, factually, and legally deficient," the statement read.
Arnold & Porter, the lead law firm representing Endo in the case, also sent NPR a statement saying it was disappointed by Moody's order. "As a firm, we are deeply committed to the integrity of the legal process," the statement said.
But A. Benjamin Spencer, dean of William & Mary Law School and an expert on civil procedure, said the judge in this case documented in detail how Endo and the company's lawyers crossed into dangerous legal territory.
"To the extent that it involves misrepresentation, falsehoods and continuing ongoing obfuscation and obstruction, I think it is extraordinary," Spencer said. "Lawyers are supposed to know better."
Drug companies face an avalanche of lawsuits over their role in the nation's deadly opioid epidemic. One question in those legal fights involves how much firms have to divulge about how they handled opioids.
This isn't the first time companies entangled in opioid litigation have faced accusations of improperly withholding documents and other key information.
But Spencer said the punishment handed down by the Tennessee court is rare and "really extreme," reflecting the gravity of misconduct identified by the judge.
While this judgment is under appeal, Moody scheduled a jury trial for July to determine the amount of damages Endo must pay for its role in Tennessee's opioid crisis.
In his order, Moody pointed to the devastation already caused by the epidemic, noting "at least three people die every day of an opioid overdose in Tennessee."
2 of 2
kek! Thanks for playing, clown.